Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ELEV Elevation Oncology	$0.37	$0.37	$0.22 ▼ $3.09	$21.62M	1.48	1.18 million shs	N/A
PLRX Pliant Therapeutics	$1.71 +2.1%	$1.48	$1.10 ▼ $16.10	$104.98M	1.43	1.67 million shs	749,076 shs
XBIT XBiotech	$2.98 -1.3%	$3.03	$2.50 ▼ $8.32	$90.85M	0.85	67,253 shs	34,695 shs
ZURA Zura Bio	$2.03 +0.5%	$1.56	$0.97 ▼ $5.07	$131.99M	-0.02	506,046 shs	143,360 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ELEV Elevation Oncology	0.00%	0.00%	0.00%	+19.99%	-53.08%
PLRX Pliant Therapeutics	+2.13%	+3.40%	+6.01%	+0.90%	-87.40%
XBIT XBiotech	-4.43%	-13.71%	+5.96%	+2.72%	-52.81%
ZURA Zura Bio	-0.98%	-0.49%	+34.67%	+71.19%	-51.09%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ELEV Elevation Oncology	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PLRX Pliant Therapeutics	4.0797 of 5 stars	3.0	2.0	0.0	4.7	3.5	1.7	0.6
XBIT XBiotech	1.8391 of 5 stars	0.0	5.0	0.0	0.0	2.2	2.5	0.6
ZURA Zura Bio	2.6551 of 5 stars	3.5	3.0	0.0	0.0	2.5	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ELEV Elevation Oncology	2.00	Hold	$2.62	616.89% Upside
PLRX Pliant Therapeutics	2.08	Hold	$8.19	378.80% Upside
XBIT XBiotech	0.00	N/A	N/A	N/A
ZURA Zura Bio	3.00	Buy	$14.00	589.66% Upside

Current Analyst Ratings Breakdown

Latest ELEV, PLRX, ZURA, and XBIT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	ZURA Zura Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$3.00 ➝ $2.00
8/15/2025	ZURA Zura Bio	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$17.00 ➝ $16.00
8/15/2025	ZURA Zura Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
8/10/2025	PLRX Pliant Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
8/8/2025	PLRX Pliant Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$17.00 ➝ $4.00
6/10/2025	ELEV Elevation Oncology	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
6/10/2025	ELEV Elevation Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Neutral
6/9/2025	ELEV Elevation Oncology	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/9/2025	ELEV Elevation Oncology	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 9/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ELEV Elevation Oncology	N/A	N/A	N/A	N/A	$1.02 per share	N/A
PLRX Pliant Therapeutics	$1.58M	66.44	N/A	N/A	$3.59 per share	0.48
XBIT XBiotech	N/A	N/A	N/A	N/A	$5.68 per share	N/A
ZURA Zura Bio	N/A	N/A	N/A	N/A	$1.96 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ELEV Elevation Oncology	-$44.49M	-$0.82	N/A	N/A	N/A	N/A	-74.68%	-48.14%	11/4/2025 (Estimated)
PLRX Pliant Therapeutics	-$210.30M	-$3.40	N/A	N/A	N/A	N/A	-73.45%	-55.66%	11/6/2025 (Estimated)
XBIT XBiotech	-$38.53M	-$0.92	N/A	∞	N/A	N/A	-15.60%	-14.64%	11/11/2025 (Estimated)
ZURA Zura Bio	-$45.39M	-$0.70	N/A	N/A	N/A	N/A	-49.11%	-40.06%	11/6/2025 (Estimated)

Latest ELEV, PLRX, ZURA, and XBIT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	ZURA Zura Bio	-$0.19	-$0.17	+$0.02	-$0.17	N/A	N/A
8/13/2025	Q2 2025	XBIT XBiotech	N/A	-$0.06	N/A	-$0.06	N/A	N/A
8/7/2025	Q2 2025	PLRX Pliant Therapeutics	-$0.62	-$0.71	-$0.09	-$0.71	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ELEV Elevation Oncology	N/A	N/A	N/A	N/A	N/A
PLRX Pliant Therapeutics	N/A	N/A	N/A	N/A	N/A
XBIT XBiotech	N/A	N/A	N/A	N/A	N/A
ZURA Zura Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ELEV Elevation Oncology	0.67	19.40	19.40
PLRX Pliant Therapeutics	0.14	12.99	12.99
XBIT XBiotech	N/A	40.16	40.16
ZURA Zura Bio	N/A	8.40	8.40

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ELEV Elevation Oncology	83.70%
PLRX Pliant Therapeutics	97.30%
XBIT XBiotech	55.70%
ZURA Zura Bio	61.14%

Insider Ownership

Company	Insider Ownership
ELEV Elevation Oncology	8.10%
PLRX Pliant Therapeutics	6.40%
XBIT XBiotech	30.80%
ZURA Zura Bio	14.23%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ELEV Elevation Oncology	40	59.22 million	54.43 million	Optionable
PLRX Pliant Therapeutics	90	61.39 million	57.46 million	Optionable
XBIT XBiotech	100	30.49 million	21.10 million	Optionable
ZURA Zura Bio	3	65.02 million	50.65 million	Optionable

ELEV, PLRX, ZURA, and XBIT Headlines

Recent News About These Companies

Zura Bio Limited (NASDAQ:ZURA) Receives Average Rating of "Buy" from Analysts

September 2 at 3:20 AM | marketbeat.com

FY2025 EPS Estimates for Zura Bio Boosted by HC Wainwright

August 23, 2025 | marketbeat.com

FY2025 EPS Estimates for Zura Bio Lifted by HC Wainwright

August 23, 2025 | americanbankingnews.com

Zura Bio (NASDAQ:ZURA) Given New $2.00 Price Target at HC Wainwright

August 21, 2025 | marketbeat.com

Zura Bio price target lowered to $2 from $3 at H.C. Wainwright

August 19, 2025 | msn.com

Q1 Earnings Estimate for Zura Bio Issued By Leerink Partnrs

August 19, 2025 | marketbeat.com

Zura Bio (NASDAQ:ZURA) Price Target Cut to $16.00 by Analysts at Oppenheimer

August 17, 2025 | marketbeat.com

Zura Bio (NASDAQ:ZURA) Earns Buy Rating from Chardan Capital

August 17, 2025 | marketbeat.com

Zura Bio (NASDAQ:ZURA) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS

August 16, 2025 | marketbeat.com

Zura Bio price target lowered to $16 from $17 at Oppenheimer

August 15, 2025 | msn.com

Zura Bio Reports Second Quarter 2025 Financial Results and Recent Corporate Updates

August 14, 2025 | businesswire.com

Zura Bio Limited (NASDAQ:ZURA) Receives Average Recommendation of "Buy" from Brokerages

August 7, 2025 | marketbeat.com

Zura Bio (ZURA) Projected to Post Quarterly Earnings on Tuesday

August 6, 2025 | marketbeat.com

Zura Bio (NASDAQ:ZURA) Shares Up 7.5% - What's Next?

August 6, 2025 | marketbeat.com

Robert Lisicki on Living Up to Zura Bio’s Heroic Namesake

July 31, 2025 | pharmexec.comP

3 Penny Stocks With Market Caps Over $70M Worth Watching

July 18, 2025 | finance.yahoo.com

Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 18, 2025 | finance.yahoo.com

Zura Bio Announces Chief Financial Officer Transition

July 1, 2025 | businesswire.com

Zura Bio shareholders approve board nominees and auditor

May 24, 2025 | investing.com

Zura Bio commences Phase II trial of tibulizumab for hidradenitis suppurativa

May 21, 2025 | msn.com

Zura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis Suppurativa

May 20, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ELEV, PLRX, ZURA, and XBIT Company Descriptions

Elevation Oncology NASDAQ:ELEV

Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.

Pliant Therapeutics NASDAQ:PLRX

$1.71 +0.04 (+2.09%)

Closing price 04:00 PM Eastern

Extended Trading

$1.65 -0.06 (-3.51%)

As of 04:17 PM Eastern

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

XBiotech NASDAQ:XBIT

$2.98 -0.04 (-1.32%)

Closing price 04:00 PM Eastern

Extended Trading

$2.98 0.00 (-0.17%)

As of 04:10 PM Eastern

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.

Zura Bio NASDAQ:ZURA

$2.03 +0.01 (+0.50%)

Closing price 04:00 PM Eastern

Extended Trading

$2.02 -0.01 (-0.49%)

As of 04:47 PM Eastern

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time